Results 111 to 120 of about 3,955 (172)

DEAD-box helicase gcDDX56 disrupts IRF3 nuclear import complex and promotes nuclear IRF3 degradation for enhancing GCRV replication. [PDF]

J Virol
Xiao LL, Chen Y, Zhang J, Xiao J, Feng H, Chang MX.   +5 more
europepmc   +1 more source

Dual targeting of solid tumors using cytokine-induced killer cells modified with a CAR anti-tenascin C and a secretable EGFRxCD3 bispecific antibody. [PDF]

Cancer Immunol Immunother
Zaninelli S, Cattaneo I, Valgardsdottir R, Frapolli R, Bello E, Meroni M, Gianatti A, Panna S, Rizzo P, Tomasoni S, D'Incalci M, Introna M, Golay J, Rambaldi A.   +13 more
europepmc   +1 more source

Evaluating patient-reported outcomes in randomized controlled trials of targeted therapy and/or immunotherapy for liver cancer: a scoping review. [PDF]

Front Oncol
Ren L, Liu Y, Li S, Yue S, Su C, Wang J, Zhang Y.   +6 more
europepmc   +1 more source

Immune Checkpoint Blockade and Emerging Combination Platforms in Breast Cancer: A Narrative Review. [PDF]

Breast Cancer (Dove Med Press)
Abbaspour M, Esmaeil N, Akbari V, Ghoreishi M, Rafiepoor H.   +4 more
europepmc   +1 more source

Advances in adoptive cell therapy for ovarian cancer. [PDF]

Front Immunol
Zhao N, An Y, Guo S, Xu Z, Shi H, Zhang Z.   +5 more
europepmc   +1 more source

Cannabidiol in pancreatic ductal adenocarcinoma: preclinical evidence, molecular mechanisms, and translational challenges. [PDF]

Cancer Cell Int
Esmaeli M, Dehghanpour Dehabadi M, Khaleghi AA.   +2 more
europepmc   +1 more source

Development and activity of canine B7-H3-CAR.CIK lymphocytes against sarcomas: preclinical evidence and perspectives for human clinical translation. [PDF]

Cancer Immunol Immunother
De Maria R, Donini C, Capellero S, Massa A, Galvagno F, Proment A, Vitali L, Vigna E, Landoni E, Dotti G, Leuci V, Accornero P, Cesar Conti L, Olimpo M, Berrino E, Grignani G, Sapino A, Sangiolo D, Aresu L.   +18 more
europepmc   +1 more source

Tumor-priming CD8⁺ natural killer T-like cells as an efficient novel cell therapy for relapsed/refractory multiple myeloma. [PDF]

Exp Hematol Oncol
Lee J, Choi E, Han B, Kim JA, Jung D, Kim KH, Oh SY, Kim SH, Ha KS, Kim JH, Lee JH, Cho D, Doh J, Kim SH.   +13 more
europepmc   +1 more source

CAR-T cell immunotherapy in rhabdomyosarcoma. [PDF]

J Transl Med
Safarzadeh Kozani P, Dashti Shokoohi S, Safarzadeh Kozani P.   +2 more
europepmc   +1 more source

The cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytes. [PDF]

Cancer Immunol Immunother
Giordano G, Merlini A, Capozzi F, Ferrero G, Tucciarello C, Majidi S, Comparato S, Mesiano G, Liuzzi E, Galvagno F, Massa A, Brusco S, Leuci V, Riganti C, Cutrupi S, De Bortoli M, D'Ambrosio L, Sangiolo D, Grignani G, Pignochino Y.   +19 more
europepmc   +1 more source